SCHEMBL277405

SCHEMBL277405

COC(=O)c1ccc(C(=O)NCCN2CCOCC2)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MMP12 P39900 4/20 0.58
MMP2 P08253 1/20 0.58
MMP8 P22894 1/20 0.58
MMP13 P45452 1/20 0.58
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
LMNA P02545 2/20 0.55
TDP1 Q9NUW8 1/20 0.54
ALDH1A1 P00352 2/20 0.54
HTR1A P08908 1/20 0.54
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54
KCNH2 Q12809 1/20 0.54
CD274 Q9NZQ7 1/20 0.54
POLB P06746 2/20 0.54
KDM4E B2RXH2 1/20 0.54
TP53 P04637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8592457 0.89 TSHR (0.57) KMT2ACYP2C9CYP2C19ALDH1A1HTR1A
SCHEMBL277183 0.88 POLB (0.56) KMT2AMEN1L3MBTL1CYP2C9ALDH1A1
SCHEMBL277558 0.87 MEN1 (0.64) KMT2AMEN1L3MBTL1MMP12LMNA
SCHEMBL279580 0.86 KMT2A (0.62) KMT2AMEN1L3MBTL1MMP12MMP2
SCHEMBL11919030 0.85 KMT2A (0.61) KMT2AMEN1L3MBTL1MMP12MMP2
SCHEMBL13354501 0.84 KMT2A (0.60) KMT2AMEN1L3MBTL1MMP12MMP2
SCHEMBL11916012 0.82 KMT2A (0.59) KMT2AMEN1L3MBTL1MMP12MMP2
SCHEMBL22515316 0.82 KMT2A (0.59) KMT2AMEN1L3MBTL1MMP12MMP2
SCHEMBL5560393 0.81 EGFR (0.51) KMT2AMEN1L3MBTL1LMNAALDH1A1
SCHEMBL3980169 0.81 MEN1 (0.74) KMT2AMEN1L3MBTL1MMP12CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KMT2A 3398/4885MEN1 605/4885L3MBTL1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.